Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-R117C
- Development stage
- Phase 2
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IMC-R117C is a bispecific T cell receptor (TCR) immunotherapy developed using Immunocore’s ImmTAC (Immune Mobilizing Monoclonal TCRs Against Cancer) platform. It targets PIWIL1, a cancer-testis antigen overexpressed in multiple malignancies including colorectal and other gastrointestinal cancers. The molecule consists of a high-affinity monoclonal TCR specific for PIWIL1 presented by HLA-A*02:01 on tumor cells, fused to an anti-CD3 effector domain that recruits and activates T cells to kill the targeted cancer cells. This design enables the immune system to recognize and destroy tumor cells expressing intracellular antigens not accessible by conventional antibody therapies. IMC-R117C is currently being evaluated in Phase 1/2 clinical trials as both monotherapy and in combination with standard-of-care treatments for advanced solid tumors expressing PIWIL1[2][3][5][7].
- Other names
- PIWIL1 x CD3 ImmTAC bispecific proteinPIWIL-1 x CD3 ImmTAC bispecific proteinPIWIL 1 x CD3 ImmTAC bispecific proteinPIWIL1 x CD3 ImmTACPIWIL-1 x CD3 ImmTACPIWIL 1 x CD3 ImmTAC
02
Targets
Piwi-like protein 1-derived peptide presented by HLA-A*02:01CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on IMC-R117C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-R117C.